Alx Oncology Holdings Inc (ALXO) Stock: Understanding the Volatility

The stock of Alx Oncology Holdings Inc (ALXO) has gone up by 3.17% for the week, with a 44.65% rise in the past month and a 12.28% rise in the past quarter. The volatility ratio for the week is 8.73%, and the volatility levels for the past 30 days are 8.81% for ALXO. The simple moving average for the past 20 days is 15.55% for ALXO’s stock, with a 68.88% simple moving average for the past 200 days.

Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?

The stock has a 36-month beta value of 1.28. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ALXO is 27.58M, and at present, short sellers hold a 13.40% of that float. On May 08, 2024, the average trading volume of ALXO was 517.92K shares.

ALXO) stock’s latest price update

Alx Oncology Holdings Inc (NASDAQ: ALXO) has experienced a rise in its stock price by 11.28 compared to its previous closing price of 15.78. However, the company has seen a gain of 3.17% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-11 that ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Analysts’ Opinion of ALXO

Many brokerage firms have already submitted their reports for ALXO stocks, with Stifel repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Stifel is $14 based on the research report published on March 08, 2024 of the current year 2024.

Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $18, previously predicting the price at $8. The rating they have provided for ALXO stocks is “Buy” according to the report published on December 08th, 2023.

Jefferies gave a rating of “Hold” to ALXO, setting the target price at $25 in the report published on December 22nd of the previous year.

ALXO Trading at 27.44% from the 50-Day Moving Average

After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.52% of gains for the given period.

Volatility was left at 8.81%, however, over the last 30 days, the volatility rate increased by 8.73%, as shares surge +42.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.75% upper at present.

During the last 5 trading sessions, ALXO rose by +3.17%, which changed the moving average for the period of 200-days by +160.92% in comparison to the 20-day moving average, which settled at $15.46. In addition, Alx Oncology Holdings Inc saw 17.93% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ALXO starting from Pons Jaume, who sale 50,000 shares at the price of $14.20 back on Apr 16 ’24. After this action, Pons Jaume now owns 604,205 shares of Alx Oncology Holdings Inc, valued at $710,195 using the latest closing price.

Pons Jaume, the PRESIDENT & CSO of Alx Oncology Holdings Inc, sale 20,000 shares at $11.15 during a trade that took place back on Apr 04 ’24, which means that Pons Jaume is holding 628,359 shares at $223,036 based on the most recent closing price.

Stock Fundamentals for ALXO

The total capital return value is set at -0.82. Equity return is now at value -70.97, with -58.58 for asset returns.

Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.63. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -217.47.

Currently, EBITDA for the company is -169.44 million with net debt to EBITDA at 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.24.

Conclusion

To sum up, Alx Oncology Holdings Inc (ALXO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts